Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 245. More products

HYDROCHLOROTHIAZIDE

7 general benefit · 5 not a benefit

Apo-Hydro 25 · DIN 00326844 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Hydro 25 · DIN 00326844 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $0.0157 Health Canada: Marketed since 2020-10-15 · brand APO-HYDROCHLOROTHIAZIDE · ATC C03AA03 HYDROCHLOROTHIAZIDE · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Hydro 25: Formulary list price $0.0157/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0157 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4281 · Verify on the e-Formulary ↗ (DIN 00326844)

Source record
DIN 00326844: Apo-Hydro 25 Raw flags: chronicUseMed=Y, sec3=Y Item: 402800012; group id 561; item number 1502; lccId None; manufacturer id APX Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0157; ministry $0.0157 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00326844 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4281
Interchangeable products
HydroDIURIL · DIN 00016500 · not recorded Mint-Hydrochlorothiazide · DIN 02426196 · $0.0157 PMS-Hydrochlorothiazide · DIN 02247386 · $0.0157 Teva-Hydrochlorothiazide · DIN 00021474 · $0.0157
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00326844
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Hydrochlorothiazide · DIN 02426196 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Hydrochlorothiazide · DIN 02426196 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2015-03-31 Daily cost (source): $0.0157 Health Canada: Marketed since 2018-08-30 · brand MINT-HYDROCHLOROTHIAZIDE · ATC C03AA03 HYDROCHLOROTHIAZIDE · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Hydrochlorothiazide: Formulary list price $0.0157/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0157 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91079 · Verify on the e-Formulary ↗ (DIN 02426196)

Source record
DIN 02426196: Mint-Hydrochlorothiazide Raw flags: chronicUseMed=Y, sec3=Y Item: 402800012; group id 561; item number 1502; lccId None; manufacturer id MIN Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0157; ministry $0.0157 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02426196 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91079
Interchangeable products
Apo-Hydro 25 · DIN 00326844 · $0.0157 HydroDIURIL · DIN 00016500 · not recorded PMS-Hydrochlorothiazide · DIN 02247386 · $0.0157 Teva-Hydrochlorothiazide · DIN 00021474 · $0.0157
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02426196
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Hydrochlorothiazide · DIN 02247386 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Hydrochlorothiazide · DIN 02247386 Manufacturer: Pharmascience Inc.; listing date 2007-09-04 Daily cost (source): $0.0157 Health Canada: Marketed since 2014-05-26 · brand PMS-HYDROCHLOROTHIAZIDE · ATC C03AA03 HYDROCHLOROTHIAZIDE · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Hydrochlorothiazide: Formulary list price $0.0157/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0157 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71631 · Verify on the e-Formulary ↗ (DIN 02247386)

Source record
DIN 02247386: PMS-Hydrochlorothiazide Raw flags: chronicUseMed=Y, sec3=Y Item: 402800012; group id 561; item number 1502; lccId None; manufacturer id PMS Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0157; ministry $0.0157 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247386 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71631
Interchangeable products
Apo-Hydro 25 · DIN 00326844 · $0.0157 HydroDIURIL · DIN 00016500 · not recorded Mint-Hydrochlorothiazide · DIN 02426196 · $0.0157 Teva-Hydrochlorothiazide · DIN 00021474 · $0.0157
Shortage status: resolved shortage (ended 2019-02-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247386
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Hydrochlorothiazide · DIN 00021474 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Hydrochlorothiazide · DIN 00021474 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Daily cost (source): $0.0157 Health Canada: Marketed since 2011-02-17 · brand TEVA-HYDROCHLOROTHIAZIDE · ATC C03AA03 HYDROCHLOROTHIAZIDE · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Hydrochlorothiazide: Formulary list price $0.0157/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0157 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=778 · Verify on the e-Formulary ↗ (DIN 00021474)

Source record
DIN 00021474: Teva-Hydrochlorothiazide Raw flags: chronicUseMed=Y, sec3=Y Item: 402800012; group id 561; item number 1502; lccId None; manufacturer id TEV Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0157; ministry $0.0157 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00021474 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=778
Interchangeable products
Apo-Hydro 25 · DIN 00326844 · $0.0157 HydroDIURIL · DIN 00016500 · not recorded Mint-Hydrochlorothiazide · DIN 02426196 · $0.0157 PMS-Hydrochlorothiazide · DIN 02247386 · $0.0157
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00021474
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Hydro 50 · DIN 00312800 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Hydro 50 · DIN 00312800 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2020-10-15 · brand APO-HYDROCHLOROTHIAZIDE · ATC C03AA03 HYDROCHLOROTHIAZIDE · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 50 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Hydro 50: Formulary list price $0.0217/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0217 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4280 · Verify on the e-Formulary ↗ (DIN 00312800)

Source record
DIN 00312800: Apo-Hydro 50 Raw flags: chronicUseMed=Y, sec3=Y Item: 402800011; group id 561; item number 1503; lccId None; manufacturer id APX Source form: Tab; strength: 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0217; ministry $0.0217 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00312800 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4280
Interchangeable products
HydroDIURIL · DIN 00016519 · not recorded PMS-Hydrochlorothiazide · DIN 02247387 · $0.0217 Teva-Hydrochlorothiazide · DIN 00021482 · $0.0217
Shortage status: shortage reported ended 2026-08-06 (report last updated 2026-08-06); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00312800
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Hydrochlorothiazide · DIN 02247387 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Hydrochlorothiazide · DIN 02247387 Manufacturer: Pharmascience Inc.; listing date 2007-09-04 Health Canada: Marketed since 2013-10-18 · brand PMS-HYDROCHLOROTHIAZIDE · ATC C03AA03 HYDROCHLOROTHIAZIDE · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 50 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Hydrochlorothiazide: Formulary list price $0.0217/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0217 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71632 · Verify on the e-Formulary ↗ (DIN 02247387)

Source record
DIN 02247387: PMS-Hydrochlorothiazide Raw flags: chronicUseMed=Y, sec3=Y Item: 402800011; group id 561; item number 1503; lccId None; manufacturer id PMS Source form: Tab; strength: 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0217; ministry $0.0217 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247387 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71632
Interchangeable products
Apo-Hydro 50 · DIN 00312800 · $0.0217 HydroDIURIL · DIN 00016519 · not recorded Teva-Hydrochlorothiazide · DIN 00021482 · $0.0217
Shortage status: resolved shortage (ended 2025-04-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247387
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Hydrochlorothiazide · DIN 00021482 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Hydrochlorothiazide · DIN 00021482 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2011-02-17 · brand TEVA-HYDROCHLOROTHIAZIDE · ATC C03AA03 HYDROCHLOROTHIAZIDE · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 50 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Hydrochlorothiazide: Formulary list price $0.0217/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0217 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=812 · Verify on the e-Formulary ↗ (DIN 00021482)

Source record
DIN 00021482: Teva-Hydrochlorothiazide Raw flags: chronicUseMed=Y, sec3=Y Item: 402800011; group id 561; item number 1503; lccId None; manufacturer id TEV Source form: Tab; strength: 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0217; ministry $0.0217 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00021482 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=812
Interchangeable products
Apo-Hydro 50 · DIN 00312800 · $0.0217 HydroDIURIL · DIN 00016519 · not recorded PMS-Hydrochlorothiazide · DIN 02247387 · $0.0217
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00021482
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Hydro · DIN 02327856 · 12.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Hydro · DIN 02327856 Manufacturer: Apotex Inc.; listing date 2010-04-23 Health Canada: Marketed since 2020-10-19 · brand APO-HYDROCHLOROTHIAZIDE · ATC C03AA03 HYDROCHLOROTHIAZIDE · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81335 · Verify on the e-Formulary ↗ (DIN 02327856)

Source record
DIN 02327856: Apo-Hydro Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 402800050; group id 561; item number 1501; lccId None; manufacturer id APX Source form: Tab; strength: 12.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.0322; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02327856 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81335
Interchangeable products
Mint-Hydrochlorothiazide · DIN 02425947 · not recorded PMS-Hydrochlorothiazide · DIN 02274086 · not recorded
Shortage status: resolved shortage (ended 2024-04-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02327856
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Hydrochlorothiazide · DIN 02425947 · 12.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Hydrochlorothiazide · DIN 02425947 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-09-25 Health Canada: Marketed since 2018-08-30 · brand MINT-HYDROCHLOROTHIAZIDE · ATC C03AA03 HYDROCHLOROTHIAZIDE · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91057 · Verify on the e-Formulary ↗ (DIN 02425947)

Source record
DIN 02425947: Mint-Hydrochlorothiazide Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 402800050; group id 561; item number 1501; lccId None; manufacturer id MIN Source form: Tab; strength: 12.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.0322; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02425947 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91057
Interchangeable products
Apo-Hydro · DIN 02327856 · not recorded PMS-Hydrochlorothiazide · DIN 02274086 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02425947
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Hydrochlorothiazide · DIN 02274086 · 12.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Hydrochlorothiazide · DIN 02274086 Manufacturer: Pharmascience Inc.; listing date 2010-04-23 Health Canada: Marketed since 2013-11-20 · brand PMS-HYDROCHLOROTHIAZIDE · ATC C03AA03 HYDROCHLOROTHIAZIDE · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Hydrochlorothiazide: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75953 · Verify on the e-Formulary ↗ (DIN 02274086)

Source record
DIN 02274086: PMS-Hydrochlorothiazide Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 402800050; group id 561; item number 1501; lccId None; manufacturer id PMS Source form: Tab; strength: 12.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02274086 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75953
Interchangeable products
Apo-Hydro · DIN 02327856 · not recorded Mint-Hydrochlorothiazide · DIN 02425947 · not recorded
Shortage status: anticipated shortage (last updated 2026-08-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02274086
Shortage record checked 2026-09-13T08:10:21.292534+00:00

HydroDIURIL · DIN 00016500 · 25mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-06-04 — choose a marketed DIN from the same-category list.Discontinued 2001-06-04 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-06-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-06-04 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
HydroDIURIL · DIN 00016500 Manufacturer: Merck Sharp & Dohme Canada, Division of Merck Frosst Canada; listing date 1996-10-01 Daily cost (source): $0.0157 Health Canada: Cancelled post market since 2001-06-04 · brand HYDRODIURIL TAB 25MG · ATC C03AA03 HYDROCHLOROTHIAZIDE · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Check this DIN again · Health Canada product record

HydroDIURIL: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=242 · Verify on the e-Formulary ↗ (DIN 00016500)

Source record
DIN 00016500: HydroDIURIL Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 402800012; group id 561; item number 1502; lccId None; manufacturer id MSD Source form: Tab; strength: 25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00016500 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=242
Interchangeable products
Apo-Hydro 25 · DIN 00326844 · $0.0157 Mint-Hydrochlorothiazide · DIN 02426196 · $0.0157 PMS-Hydrochlorothiazide · DIN 02247386 · $0.0157 Teva-Hydrochlorothiazide · DIN 00021474 · $0.0157
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00016500
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2001-06-04 — choose a marketed DIN from the same-category list.

HydroDIURIL · DIN 00016519 · 50mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.Discontinued 2000-08-03 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
HydroDIURIL · DIN 00016519 Manufacturer: Merck Sharp & Dohme Canada, Division of Merck Frosst Canada; listing date 1996-10-01 Health Canada: Cancelled post market since 2000-08-03 · brand HYDRODIURIL TAB 50MG · ATC C03AA03 HYDROCHLOROTHIAZIDE · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 50 MG · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Check this DIN again · Health Canada product record

HydroDIURIL: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=243 · Verify on the e-Formulary ↗ (DIN 00016519)

Source record
DIN 00016519: HydroDIURIL Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 402800011; group id 561; item number 1503; lccId None; manufacturer id MSD Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00016519 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=243
Interchangeable products
Apo-Hydro 50 · DIN 00312800 · $0.0217 PMS-Hydrochlorothiazide · DIN 02247387 · $0.0217 Teva-Hydrochlorothiazide · DIN 00021482 · $0.0217
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00016519
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.

AMILORIDE HCL & HYDROCHLOROTHIAZIDE

1 general benefit · 1 not a benefit

AA-Amilzide · DIN 00784400 · 5mg & 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Amilzide · DIN 00784400 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $0.0484 Health Canada: Marketed since 2019-10-30 · brand AA-AMILZIDE · ATC C03EA01 HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS, C03EA01 HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS · form Tablet · route Oral · ingredients AMILORIDE HYDROCHLORIDE 5 MG, HYDROCHLOROTHIAZIDE 50 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

AA-Amilzide: Formulary list price $0.0969/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0969 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10494 · Verify on the e-Formulary ↗ (DIN 00784400)

Source record
DIN 00784400: AA-Amilzide Raw flags: chronicUseMed=Y, sec3=Y Item: 402800032; group id 556; item number 1494; lccId None; manufacturer id AAP Source form: Tab; strength: 5mg & 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0969; ministry $0.0969 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00784400 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10494
Interchangeable products
Moduret · DIN 00487813 · not recorded
Shortage status: resolved shortage (ended 2024-07-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00784400
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Moduret · DIN 00487813 · 5mg & 50mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-08-05 — choose a marketed DIN from the same-category list.Discontinued 2009-08-05 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-08-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-08-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Moduret · DIN 00487813 Manufacturer: Prempharm Inc.; listing date 1996-10-01 Daily cost (source): $0.0484 Health Canada: Cancelled post market since 2009-08-05 · brand MODURET · ATC C03EA01 HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS, C03EA01 HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS · form Tablet · route Oral · ingredients AMILORIDE HYDROCHLORIDE 5 MG, HYDROCHLOROTHIAZIDE 50 MG · company Prempharm inc · schedule Prescription
Check this DIN again · Health Canada product record

Moduret: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4118 · Verify on the e-Formulary ↗ (DIN 00487813)

Source record
DIN 00487813: Moduret Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 402800032; group id 556; item number 1494; lccId None; manufacturer id PRE Source form: Tab; strength: 5mg & 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00487813 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4118
Interchangeable products
AA-Amilzide · DIN 00784400 · $0.0969
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00487813
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2009-08-05 — choose a marketed DIN from the same-category list.

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Atacand Plus · DIN 02244021 · 16mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Atacand Plus · DIN 02244021 Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 2002-07-29 Health Canada: Marketed since 2025-06-10 · brand ATACAND PLUS · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients CANDESARTAN CILEXETIL 16 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2156 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67964 · Verify on the e-Formulary ↗ (DIN 02244021)

Source record
DIN 02244021: Atacand Plus Raw flags: chronicUseMed=Y, sec3=Y Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id CHE Source form: Tab; strength: 16mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6162; ministry $0.2156 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244021 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67964
Interchangeable products
Auro-Candesartan HCT · DIN 02421038 · $0.2156 Candesartan HCT · DIN 02394812 · $0.2156 Candesartan/HCTZ · DIN 02394804 · $0.2156 Jamp Candesartan-HCT · DIN 02473240 · $0.2156 NRA-Candesartan HCTZ · DIN 02531240 · $0.2156 PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156 Sandoz Candesartan Plus · DIN 02327902 · $0.2156 Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: resolved shortage (ended 2019-03-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244021
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Candesartan HCT · DIN 02421038 · 16mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Candesartan HCT · DIN 02421038 Manufacturer: Auro Pharma Inc.; listing date 2015-05-28 Health Canada: Marketed since 2015-03-17 · brand AURO-CANDESARTAN HCT · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 16 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Candesartan HCT: Formulary list price $0.2156/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2156 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90562 · Verify on the e-Formulary ↗ (DIN 02421038)

Source record
DIN 02421038: Auro-Candesartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id AUR Source form: Tab; strength: 16mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2156; ministry $0.2156 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02421038 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90562
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156 Candesartan HCT · DIN 02394812 · $0.2156 Candesartan/HCTZ · DIN 02394804 · $0.2156 Jamp Candesartan-HCT · DIN 02473240 · $0.2156 NRA-Candesartan HCTZ · DIN 02531240 · $0.2156 PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156 Sandoz Candesartan Plus · DIN 02327902 · $0.2156 Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: resolved shortage (ended 2025-02-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02421038
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Candesartan HCT · DIN 02394812 · 16mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Candesartan HCT · DIN 02394812 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2012-10-18 · brand CANDESARTAN HCT · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 16 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Candesartan HCT: Formulary list price $0.2156/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2156 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87997 · Verify on the e-Formulary ↗ (DIN 02394812)

Source record
DIN 02394812: Candesartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id SIV Source form: Tab; strength: 16mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2156; ministry $0.2156 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02394812 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87997
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156 Auro-Candesartan HCT · DIN 02421038 · $0.2156 Candesartan/HCTZ · DIN 02394804 · $0.2156 Jamp Candesartan-HCT · DIN 02473240 · $0.2156 NRA-Candesartan HCTZ · DIN 02531240 · $0.2156 PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156 Sandoz Candesartan Plus · DIN 02327902 · $0.2156 Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02394812
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Candesartan/HCTZ · DIN 02394804 · 16mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Candesartan/HCTZ · DIN 02394804 Manufacturer: Sanis Health Inc.; listing date 2020-08-28 Health Canada: Marketed since 2024-02-21 · brand CANDESARTAN/HCTZ · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 16 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Candesartan/HCTZ: Formulary list price $0.2156/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2156 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87995 · Verify on the e-Formulary ↗ (DIN 02394804)

Source record
DIN 02394804: Candesartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id SAI Source form: Tab; strength: 16mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2156; ministry $0.2156 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02394804 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87995
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156 Auro-Candesartan HCT · DIN 02421038 · $0.2156 Candesartan HCT · DIN 02394812 · $0.2156 Jamp Candesartan-HCT · DIN 02473240 · $0.2156 NRA-Candesartan HCTZ · DIN 02531240 · $0.2156 PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156 Sandoz Candesartan Plus · DIN 02327902 · $0.2156 Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: resolved shortage (ended 2025-04-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02394804
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Candesartan-HCT · DIN 02473240 · 16mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Candesartan-HCT · DIN 02473240 Manufacturer: Jamp Pharma Corporation; listing date 2019-07-31 Health Canada: Marketed since 2020-03-23 · brand JAMP CANDESARTAN-HCT · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 16 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Candesartan-HCT: Formulary list price $0.2156/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2156 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96264 · Verify on the e-Formulary ↗ (DIN 02473240)

Source record
DIN 02473240: Jamp Candesartan-HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id JPC Source form: Tab; strength: 16mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2156; ministry $0.2156 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02473240 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96264
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156 Auro-Candesartan HCT · DIN 02421038 · $0.2156 Candesartan HCT · DIN 02394812 · $0.2156 Candesartan/HCTZ · DIN 02394804 · $0.2156 NRA-Candesartan HCTZ · DIN 02531240 · $0.2156 PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156 Sandoz Candesartan Plus · DIN 02327902 · $0.2156 Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: resolved shortage (ended 2024-05-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02473240
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Candesartan HCTZ · DIN 02531240 · 16mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Candesartan HCTZ · DIN 02531240 Manufacturer: Nora Pharma; listing date 2023-12-29 Health Canada: Marketed since 2023-07-20 · brand NRA-CANDESARTAN HCTZ · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients CANDESARTAN CILEXETIL 16 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Candesartan HCTZ: Formulary list price $0.2156/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2156 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102039 · Verify on the e-Formulary ↗ (DIN 02531240)

Source record
DIN 02531240: NRA-Candesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id NRA Source form: Tab; strength: 16mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2156; ministry $0.2156 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02531240 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102039
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156 Auro-Candesartan HCT · DIN 02421038 · $0.2156 Candesartan HCT · DIN 02394812 · $0.2156 Candesartan/HCTZ · DIN 02394804 · $0.2156 Jamp Candesartan-HCT · DIN 02473240 · $0.2156 PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156 Sandoz Candesartan Plus · DIN 02327902 · $0.2156 Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531240
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Candesartan-HCTZ · DIN 02391295 · 16mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Candesartan-HCTZ · DIN 02391295 Manufacturer: Pharmascience Inc.; listing date 2012-11-27 Health Canada: Marketed since 2012-09-24 · brand PMS-CANDESARTAN-HCTZ · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients CANDESARTAN CILEXETIL 16.0 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Candesartan-HCTZ: Formulary list price $0.2156/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2156 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87664 · Verify on the e-Formulary ↗ (DIN 02391295)

Source record
DIN 02391295: PMS-Candesartan-HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id PMS Source form: Tab; strength: 16mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2156; ministry $0.2156 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02391295 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87664
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156 Auro-Candesartan HCT · DIN 02421038 · $0.2156 Candesartan HCT · DIN 02394812 · $0.2156 Candesartan/HCTZ · DIN 02394804 · $0.2156 Jamp Candesartan-HCT · DIN 02473240 · $0.2156 NRA-Candesartan HCTZ · DIN 02531240 · $0.2156 Sandoz Candesartan Plus · DIN 02327902 · $0.2156 Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: resolved shortage (ended 2019-02-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02391295
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Candesartan Plus · DIN 02327902 · 16mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Candesartan Plus · DIN 02327902 Manufacturer: Sandoz Canada Inc.; listing date 2012-11-27 Health Canada: Marketed since 2012-09-24 · brand SANDOZ CANDESARTAN PLUS · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients CANDESARTAN CILEXETIL 16 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Candesartan Plus: Formulary list price $0.2156/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2156 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81340 · Verify on the e-Formulary ↗ (DIN 02327902)

Source record
DIN 02327902: Sandoz Candesartan Plus Raw flags: chronicUseMed=Y, sec3=Y Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id SDZ Source form: Tab; strength: 16mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2156; ministry $0.2156 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02327902 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81340
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156 Auro-Candesartan HCT · DIN 02421038 · $0.2156 Candesartan HCT · DIN 02394812 · $0.2156 Candesartan/HCTZ · DIN 02394804 · $0.2156 Jamp Candesartan-HCT · DIN 02473240 · $0.2156 NRA-Candesartan HCTZ · DIN 02531240 · $0.2156 PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156 Teva-Candesartan/HCTZ · DIN 02395541 · $0.2156
Shortage status: anticipated shortage (last updated 2026-09-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02327902
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Candesartan/HCTZ · DIN 02395541 · 16mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Candesartan/HCTZ · DIN 02395541 Manufacturer: Teva Canada Limited; listing date 2012-12-21 Health Canada: Marketed since 2013-09-23 · brand TEVA-CANDESARTAN/HCTZ · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 16 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Candesartan/HCTZ: Formulary list price $0.2156/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2156 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88063 · Verify on the e-Formulary ↗ (DIN 02395541)

Source record
DIN 02395541: Teva-Candesartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800248; group id 315; item number 0696; lccId None; manufacturer id TEV Source form: Tab; strength: 16mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2156; ministry $0.2156 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02395541 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88063
Interchangeable products
Atacand Plus · DIN 02244021 · $0.2156 Auro-Candesartan HCT · DIN 02421038 · $0.2156 Candesartan HCT · DIN 02394812 · $0.2156 Candesartan/HCTZ · DIN 02394804 · $0.2156 Jamp Candesartan-HCT · DIN 02473240 · $0.2156 NRA-Candesartan HCTZ · DIN 02531240 · $0.2156 PMS-Candesartan-HCTZ · DIN 02391295 · $0.2156 Sandoz Candesartan Plus · DIN 02327902 · $0.2156
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02395541
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Atacand Plus · DIN 02332922 · 32mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Atacand Plus · DIN 02332922 Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 2010-07-20 Health Canada: Marketed since 2025-06-19 · brand ATACAND PLUS · ATC C09DA06 CANDERSARTAN AND DIURETICS, C09DA06 CANDERSARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CANDESARTAN CILEXETIL 32 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2156 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81858 · Verify on the e-Formulary ↗ (DIN 02332922)

Source record
DIN 02332922: Atacand Plus Raw flags: chronicUseMed=Y, sec3=Y Item: 240800291; group id 315; item number 0697; lccId None; manufacturer id CHE Source form: Tab; strength: 32mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6162; ministry $0.2156 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02332922 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81858
Interchangeable products
Auro-Candesartan HCT · DIN 02421046 · $0.2156 Candesartan/HCTZ · DIN 02536064 · $0.2156 Jamp Candesartan-HCT · DIN 02473259 · $0.2156 NRA-Candesartan HCTZ · DIN 02531259 · $0.2156 Sandoz Candesartan Plus · DIN 02420732 · $0.2156 Teva-Candesartan/HCTZ · DIN 02395568 · $0.2156
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02332922
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, LABETALOL HCL, LOSARTAN POTASSIUM, MINOXIDIL, OLMESARTAN MEDOXOMIL, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, LISINOPRIL, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, RAMIPRIL, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

CLONIDINE HCL

· 17 products · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) · strengths: 0.025mg, 0.1mg, 0.2mg · Tab

DOXAZOSIN MESYLATE

· 12 products · Listed, not a benefit (3), General benefit (9) · strengths: 1mg, 2mg, 4mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FELODIPINE

· 12 products · General benefit (10), Listed, not a benefit (2) · strengths: 2.5mg, 5mg, 10mg · ER Tab, SR Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab

HYDRALAZINE HCL

· 17 products · General benefit (14), Listed, not a benefit (3) · strengths: 20mg/mL, 10mg, 25mg, 50mg · Inj Sol-1mL Vial Pk, Tab

IRBESARTAN

· 41 products · Listed, not a benefit (1), General benefit (40) · strengths: 75mg, 150mg, 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 23 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors

Other drugs in the same formulary class (40:28 Diuretics) and how they are covered

Matched class: 40:28 Diuretics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMILORIDE HCL, METOLAZONE, SPIRONOLACTONE Some products covered without a code (check the product listing): CHLORTHALIDONE, FUROSEMIDE, INDAPAMIDE 40:28 Diuretics

AMILORIDE HCL

· 1 products · General benefit · strengths: 5mg · Tab

CHLORTHALIDONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 50mg · Tab

FUROSEMIDE

· 14 products · Limited Use, codes 481, 657 (2), General benefit (9), Listed, not a benefit (2), Limited Use, codes 33 (1) · strengths: 10mg/mL, 20mg, 40mg, 500mg · Inj Sol (Preservative Free), O/L, Tab

INDAPAMIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1.25mg, 2.5mg · Tab

METOLAZONE

· 1 products · General benefit · strengths: 2.5mg · Tab

SPIRONOLACTONE

· 8 products · General benefit · strengths: 25mg, 100mg · Tab

MIDODRINE HCL

· 10 products · Listed, not a benefit (2), Limited Use, codes 01 (8) · strengths: 2.5mg, 5mg · Tab

TOLVAPTAN

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 15mg & 15mg, 30mg & 15mg, 45mg & 15mg, 60mg & 30mg, 90mg & 30mg · 14-Tabs Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:28
Full class listing Related classes: 40:12 Replacement Agents, 40:18 Potassium-Removing Resins, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, LABETALOL HCL ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6) INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10 Product monograph AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) 1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph FELODIPINE · General benefit (10), Listed, not a benefit (2) 1 INDICATIONS PLENDIL (felodipine) is indicated for: • the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082730.PDF; date 2025-12-09; DIN 00851779; fetched 2026-09-10 Product monograph HYDRALAZINE HCL · General benefit (14), Listed, not a benefit (3) Indications APO-HYDRALAZINE (hydralazine hydrochloride tablets) is indicated for:  Treatment of essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080783.PDF; date 2025-05-14; DIN 00441619; fetched 2026-09-10 Product monograph LABETALOL HCL · General benefit Indications TRANDATE (labetalol hydrochloride tablets) is indicated for: • the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00082955.PDF; date not captured; DIN 02106272; fetched 2026-09-10 Product monograph and 12 more Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-HYDROCHLOROTHIAZIDE (Hydrochlorothiazide) is indicated for the treatment of: • Edema • Hypertension • Toxemia of Pregnancy Edema TEVA-HYDROCHLOROTHIAZIDE (hydrochlorothiazide) is indicated in edema associated with congestive heart failure, hepatic cirrhosis, corticosteroid and estrogen therapy, premenstrual tension with edema and in edema of renal origin (i.e. nephrotic syndrome, acute glomerulonephritis and chronic renal disease). In obese patients in whom fluid retention is a complicating factor, it may help to initiate a loss of fluid and, thus of weight. Hypertension TEVA-HYDROCHLOROTHIAZIDE may be used alone or as an adjunct to other antihypertensive drugs. Since it enhances the action of these agents, their dosage must be reduced to avoid an excessive drop in pressure and other unwanted side effects. Toxemia of Pregnancy TEVA-HYDROCHLOROTHIAZIDE may be effective in the treatment of toxemia of pregnancy (including eclampsia). TEVA-HYDROCHLOROTHIAZIDE Product Monograph Page 3 of 23 Geriatrics (> 65 years of age): No data is available. Pediatrics (0 to 12 years of age): See WA… https://pdf.hres.ca/dpd_pm/00074131.PDF PM date: December 29, 2023 Source product: TEVA-HYDROCHLOROTHIAZIDE; DIN 00021474; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS AA-AMILZIDE (amiloride hydrochloride and hydrochlorothiazide tablet) is indicated in the maintenance therapy of patients with: ▪ hepatic cirrhosis with ascites and edema. ▪ edema of cardiac origin or with arterial hypertension who are hypokalemic or in whom maintenance of normal potassium levels is considered to be clinically important i.e., digitalized patients, patients in whom adequate dietary intake of potassium is not feasible or patients with cardiac arrhythmias. Use in Hepatic Cirrhosis with Ascites and Edema Amiloride hydrochloride used alone may provide satisfactory diuresis with diminished potassium loss and with a reduced risk of metabolic alkalosis. In resistant cases amiloride hydrochloride may be used with kaliuretic-diuretic agents to help produce satisfactory diuresis, while maintaining a more balanced serum electrolyte pattern. As with all therapy for the ascites of hepatic cirrhosis, gradual weight loss and avoidance of electrolyte imbalance are the chief objectives (See 7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic). 1.1 Pediatrics Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada… https://pdf.hres.ca/dpd_pm/00069954.PDF PM date: MAR 13, 2019 Source product: AA-AMILZIDE; DIN 00784400; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. ATACAND PLUS is not indicated for initial therapy (see 4 DOSAGE AND ADMINISTRATION). The dosage of ATACAND PLUS must be individualized. The dose of ATACAND PLUS should be determined by titration of the individual components. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (> 65 years of age): No overall differences in safety or effectiveness were observed between the younger and elderly patients but greater sensitivity of some older patients cannot be ruled out and appropriate caution is recommended (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00076288.PDF PM date: JUN 18, 2001 Source product: ATACAND PLUS; DIN 02244021; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. INHIBACE PLUS is not indicated for initial therapy. Patients should be titrated on the individual drugs. The safety and efficacy of INHIBACE PLUS in congestive heart failure and renovascular hypertension have not been established and therefore, its use in these conditions is not recommended. The safety and efficacy of concomitant use of cilazapril with antihypertensive agents other than thiazide diuretics have not been established. 1.1 Pediatrics Pediatrics (birth - <18 years): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of INHIBACE PLUS in pediatric patients has not been established. Therefore, Health Canada has not authorized an indication for this age group. 1.2 Geriatrics Although clinical experience has not identified differences in response between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out (see 7 WARNINGS AND PRECAUTIO… https://pdf.hres.ca/dpd_pm/00066994.PDF PM date: September 07, 1995 Source product: INHIBACE PLUS; DIN 02181479; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:  Treatment of essential hypertension in patients for whom this combination therapy with enalapril and hydrochlorothiazide is appropriate. In using VASERETIC® consideration should be given to the risk of angioedema (see 7 WARNINGS AND PRECAUTIONS - General). VASERETIC® is not indicated for initial therapy. 1.1 Pediatrics Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of VASERETIC® has not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. https://pdf.hres.ca/dpd_pm/00068096.PDF PM date: November 4, 2022 Source product: VASERETIC; DIN 00657298; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found
What the Health Canada label says it is for
1 INDICATIONS Fixed-dose combination drugs are not indicated for initial therapy. Patients should be titrated on the individual drugs. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. If during maintenance therapy dosage adjustment is necessary, it is advisable to use the individual drugs. TEVA-SPIRONOLACTONE/HCTZ (spironolactone and hydrochlorothiazide) is indicated for:  Edematous conditions for patients with Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate. The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. TEVA-SPIRONOLACTONE/HCTZ is indicated for… https://pdf.hres.ca/dpd_pm/00067931.PDF PM date: June 28, 2011 Source product: TEVA-SPIRONOLACTONE/HCTZ; DIN 00613231; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications APO-TRIAZIDE (Triamterene and Hydrochlorothiazide) is indicated in the maintenance therapy of: • Patients with edema associated with congestive heart failure, hepatic cirrhosis, and nephrotic syndrome; also in steroid induced edema and idiopathic edema. • Patients with mild to moderate hypertension in those patients who have developed hypokalemia while on thiazide-like diuretics alone, and in those patients in whom potassium depletion is considered especially dangerous (e.g. digitalized patients). Medical opinion is not unanimous regarding the incidence and/or clinical significance of hypokalemia occurring among hypertensive patients treated with thiazide-like diuretics alone, and concerning the use of potassium-sparing combinations as routine therapy in hypertension. Fixed-dose combination drugs are not indicated for initial therapy. Patients should be titrated on the individual drugs. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. If during maintenance therapy dosage adjustment is necessary it is advisable to us… https://pdf.hres.ca/dpd_pm/00085869.PDF PM date: 2026-08-25 Source product: APO-TRIAZIDE; DIN 00441775; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications AVALIDE® (irbesartan/hydrochlorothiazide) is indicated: • for the treatment of essential hypertension in patients for whom combination therapy is appropriate (see DOSAGE AND ADMINISTRATION). • as initial therapy in patients with severe essential hypertension (Sitting DBP ≥ 110 mmHg) for whom the benefit of a prompt blood pressure reduction exceeds the risk of initiating combination therapy in these patients (see CLINICAL TRIALS and DOSAGE AND ADMINISTRATION). AVALIDE is not indicated as initial therapy in patients with mild to moderate essential hypertension. 1.1. Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of AVALIDE in patients <18 years of age have not been established. Therefore, Health Canada has not authorized an indication for pediatric use (see WARNINGS AND PRECAUTIONS, Special Populations). 1.2. Geriatrics Geriatrics (> 65 years of age): In clinical studies, no overall differences in safety or efficacy were observed between patients > 65 years of age and younger patients (see WARNINGS AND PRECAUTIONS, Special Populations). https://pdf.hres.ca/dpd_pm/00081257.PDF PM date: not printed or not captured Source product: AVALIDE; DIN 02241818; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS ZESTORETIC (lisinopril and hydrochlorothiazide) is indicated for: • The treatment of essential hypertension in patients for whom combination therapy is appropriate. ZESTORETIC is not indicated for initial therapy (see 4 DOSAGE AND ADMINISTRATION). Patients in whom lisinopril and diuretic are initiated simultaneously can develop symptomatic hypotension (see 9 DRUG INTERACTIONS). ZESTORETIC is not indicated for the treatment of renovascular hypertension (see 7 WARNINGS AND PRECAUTIONS, Hypotension). 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (> 65 years of age): In general, blood pressure response and adverse experiences were similar in younger and older patients given similar doses of lisinopril (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00073386.PDF PM date: not printed or not captured Source product: ZESTORETIC; DIN 02045729; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications Hypertension: HYZAAR® (losartan potassium and hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate HYZAAR is not indicated as the initial therapy for essential hypertension, except in patients with severe essential hypertension (Sitting DBP ≥110 mmHg) for whom the benefit of a prompt blood pressure reduction exceeds the risk of initiating combination therapy in these patients (see 4 Dosage And Administration and 14 Clinical Trials) 1.1. Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (>65 years of age): No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out (see 4 Dosage And Administration). https://pdf.hres.ca/dpd_pm/00080943.PDF PM date: 2025-06-19 Source product: HYZAAR; DIN 02230047; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 Indications OLMETEC PLUS® (olmesartan medoxomil and hydrochlorothiazide) is indicated for: • treatment of mild to moderate essential hypertension in patients for whom combination therapy is appropriate. OLMETEC PLUS is not indicated for initial therapy (see 4 Dosage and Administration). 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Reported clinical experience has not identified differences in responses between elderly and younger patients, however, greater sensitivity of some older individuals cannot be ruled out (see 4 Dosage and Administration). https://pdf.hres.ca/dpd_pm/00085993.PDF PM date: 2026-09-03 Source product: OLMETEC PLUS; DIN 02319616; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found
What the Health Canada label says it is for
1 INDICATIONS APO-QUINAPRIL/HCTZ (quinapril hydrochloride and hydrochlorothiazide) is indicated for the treatment of essential hypertension in patients for whom combination therapy is appropriate. APO-QUINAPRIL/HCTZ is not indicated for initial therapy. Patients in whom quinapril and hydrochlorothiazide are initiated simultaneously can develop symptomatic hypotension (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular, - Hypotension and 9 DRUG INTERACTIONS). Patients should be titrated on the individual drugs. If the fixed combination represents the dosage determined by this titration, the use of APO-QUINAPRIL/HCTZ may be more convenient in the management of patients. If during maintenance therapy dosage adjustment is necessary, it is advisable to use individual drugs. 1.1 Pediatrics (<18 years of age) Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics (> 65 years of age) Therapeutic effects appear to be the same for elderly (>65 years of age) and younger adult patients given the same daily dosages, with no increase in adverse events in elderly pa… https://pdf.hres.ca/dpd_pm/00074827.PDF PM date: MAR 05, 2024 Source product: APO-QUINAPRIL/HCTZ; DIN 02408767; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS pms-RAMIPRIL-HCTZ (ramipril/hydrochlorothiazide) is indicated for the treatment of essential hypertension in patients for whom this combination therapy is appropriate. pms-RAMIPRIL-HCTZ is not indicated for initial therapy (see 4 DOSAGE AND ADMINISTRATION). Patients in whom ramipril and diuretic are initiated simultaneously can develop symptomatic hypotension. Patients should be titrated on individual drugs. If the fixed combination represents the dose and dosing frequency determined by this titration, the use of pms-RAMIPRIL-HCTZ may be more convenient in the management of patients. If during maintenance therapy dosage adjustment is necessary, it is advisable to use the individual drugs. Pediatrics Pediatrics (< 18 years of age): The safety and effectiveness of ramipril and hydrochlorothiazide in pediatric patients have not been established. Therefore, pms-RAMIPRIL-HCTZ is not indicated in this patient population. Geriatrics Geriatrics (> 65 years of age): There is limited clinical experience with ramipril and hydrochlorothiazide in the elderly (> 65 years) (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00071439.PDF PM date: June 20, 2023 Source product: PMS-RAMIPRIL-HCTZ; DIN 02342154; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS MICARDIS PLUS (80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated for: • treatment of mild to moderate essential hypertension in patients in whom combination therapy with telmisartan and hydrochlorothiazide is considered appropriate. MICARDIS PLUS (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated for: • treatment of patients whose blood pressure is not adequately controlled by MICARDIS PLUS 80 mg/12.5 mg or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. These fixed-dose combinations are not indicated as initial therapy (see 4 DOSAGE AND ADMINISTRATION). 1.1 Pediatrics • Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of MICARDIS PLUS in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics • Geriatrics (> 65 years of age): No dosage adjustment is necessary. It should be recognized, however, that greater sensitivity in some older individual… https://pdf.hres.ca/dpd_pm/00077923.PDF PM date: NOV 28, 2024 Source product: MICARDIS PLUS; DIN 02244344; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS DIOVAN-HCT® (valsartan and hydrochlorothiazide tablets) is indicated for: • the treatment of mild to moderate essential hypertension in patients for whom combination therapy is appropriate. DIOVAN-HCT is not indicated for initial therapy (see 4 DOSAGE AND ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed combination represents the dose and dosing frequency determined by this titration, the use of DIOVAN-HCT may be more convenient in the management of patients. If during maintenance therapy dosage adjustment is necessary it is advisable to use the individual drugs. 1.1 Pediatrics (< 18 years of age): The safety and efficacy of DIOVAN-HCT in children and adolescents (below the age of 18 years) have not been established and use in this age group is not recommended. 1.2 Geriatrics (> 65 years of age): No overall age-related differences were seen in the adverse effect profile but greater sensitivity in some older individuals cannot be ruled out and appropriate caution is recommended. https://pdf.hres.ca/dpd_pm/00069736.PDF PM date: March 15, 2000 Source product: DIOVAN-HCT; DIN 02241900; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Hydrochlorothiazide · DIN 00021474 Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00021474

Check this DIN again

Apo-Hydro 50 · DIN 00312800 Shortage status: shortage reported ended 2026-08-06 (report last updated 2026-08-06); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00312800

Check this DIN again

Teva-Hydrochlorothiazide · DIN 00021482 Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00021482

Check this DIN again

Teva-Candesartan/HCTZ · DIN 02395541 Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02395541

Check this DIN again

Other review policies

For Apo-Hydro, Mint-Hydrochlorothiazide, PMS-Hydrochlorothiazide, HydroDIURIL, Moduret: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026